Acer Therapeutics shares are trading lower after the company reported worse-than-expected Q2 EPS results.
Portfolio Pulse from Benzinga Newsdesk
Acer Therapeutics reported worse-than-expected Q2 earnings per share (EPS) results, leading to a decrease in its share price.
August 15, 2023 | 4:57 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Acer Therapeutics' Q2 EPS results were below expectations, causing a drop in its stock price.
Acer Therapeutics' worse-than-expected Q2 EPS results have negatively impacted investor sentiment, leading to a decrease in its stock price. This indicates a potential short-term downward trend for ACER's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100